Immix Biopharma (IMMX) Income from Non-Controlling Interests (2023 - 2024)
Immix Biopharma's (IMMX) quarterly Income from Non-Controlling Interests came in at -$12914.0 in Q2 2024, up 41.29% year-on-year from -$9140.1 in Q3 2023, and up 82.08% quarter-over-quarter from -$72073.0 in Q1 2024.
Immix Biopharma (IMMX) Income from Non-Controlling Interests (2023 - 2024) Analysis & Trends
Immix Biopharma has disclosed Income from Non-Controlling Interests across 2 years of filings, most recently posting -$12914.0 for Q2 2024.
- Income from Non-Controlling Interests for Q2 2024 came in at -$12914.0, up 41.29% year-over-year; the trailing twelve-month figure through Dec 2024 was -$84987.0 (up 49.85% YoY), and the FY2024 annual result was -$84987.0, up 49.85% from the prior year.
- Income from Non-Controlling Interests came in at -$12914.0 for Q2 2024 at Immix Biopharma, up from -$72073.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$12914.0 in Q2 2024 to a low of -$72073.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Immix Biopharma | 467.59 Mn | 467.59 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -12,914.00 |
| Mar 31, 2024 | -72,073.00 |
| Dec 31, 2023 | -65,862.00 |
| Sep 30, 2023 | -63,248.00 |
| Jun 30, 2023 | -21,996.00 |
| Mar 31, 2023 | -18,368.00 |